HK1056509A1 - Liquid spray formulations for buccal delivery of cannabinoids - Google Patents

Liquid spray formulations for buccal delivery of cannabinoids

Info

Publication number
HK1056509A1
HK1056509A1 HK03108883.0A HK03108883A HK1056509A1 HK 1056509 A1 HK1056509 A1 HK 1056509A1 HK 03108883 A HK03108883 A HK 03108883A HK 1056509 A1 HK1056509 A1 HK 1056509A1
Authority
HK
Hong Kong
Prior art keywords
cannabinoids
liquid spray
spray formulations
buccal delivery
buccal
Prior art date
Application number
HK03108883.0A
Other languages
English (en)
Inventor
Brian Whittle
Geoffrey Guy
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27546617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1056509(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0103638A external-priority patent/GB0103638D0/en
Priority claimed from US09/827,158 external-priority patent/US6730330B2/en
Priority claimed from GB0111597A external-priority patent/GB2377633A/en
Priority claimed from GB0121715A external-priority patent/GB2381194A/en
Priority claimed from US09/951,022 external-priority patent/US7025992B2/en
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of HK1056509A1 publication Critical patent/HK1056509A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03108883.0A 2001-02-14 2003-12-05 Liquid spray formulations for buccal delivery of cannabinoids HK1056509A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0103638A GB0103638D0 (en) 2001-02-14 2001-02-14 Pharmaceutical formulations
US28004401P 2001-03-30 2001-03-30
US09/827,158 US6730330B2 (en) 2001-02-14 2001-04-05 Pharmaceutical formulations
GB0111597A GB2377633A (en) 2001-05-11 2001-05-11 Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB0121715A GB2381194A (en) 2001-09-07 2001-09-07 Pharmaceutical formulations
US09/951,022 US7025992B2 (en) 2001-02-14 2001-09-12 Pharmaceutical formulations
PCT/GB2002/000620 WO2002064109A2 (en) 2001-02-14 2002-02-14 Mucoadhesive pharmaceutical formulations

Publications (1)

Publication Number Publication Date
HK1056509A1 true HK1056509A1 (en) 2004-02-20

Family

ID=27546617

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108883.0A HK1056509A1 (en) 2001-02-14 2003-12-05 Liquid spray formulations for buccal delivery of cannabinoids

Country Status (20)

Country Link
EP (5) EP2286793A3 (de)
JP (1) JP4467883B2 (de)
KR (1) KR100886668B1 (de)
AU (1) AU2002231970B2 (de)
CA (1) CA2438097C (de)
CZ (1) CZ306277B6 (de)
DE (1) DE10296335T5 (de)
DK (1) DK1361864T3 (de)
ES (1) ES2444641T3 (de)
GB (1) GB2388543A (de)
HK (1) HK1056509A1 (de)
HU (1) HU227452B1 (de)
IL (1) IL157130A0 (de)
MX (1) MXPA03007215A (de)
NO (1) NO334743B1 (de)
NZ (1) NZ527289A (de)
PT (1) PT1361864E (de)
SI (1) SI1361864T1 (de)
WO (1) WO2002064109A2 (de)
ZA (1) ZA200306074B (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
WO2003063847A1 (en) * 2002-02-01 2003-08-07 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
CA2994322A1 (en) * 2002-08-14 2004-02-14 Gw Pharma Limited Botanical drug substances comprising various proportions of thc and cbd
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
KR101008609B1 (ko) 2002-08-14 2011-01-17 지더블유 파마 리미티드 점막투여용 칸나비노이드 액체 제형
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2005000830A1 (en) 2003-06-24 2005-01-06 Gw Pharma Limited Pharmaceutical compositions comprising cabbinochreme type compounds
ES2235626B1 (es) * 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
JP5153341B2 (ja) 2004-12-09 2013-02-27 インシス セラピューティクス，インコーポレーテッド 室温で安定なドロナビノール製剤
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
AU2007295179B2 (en) * 2006-09-15 2013-05-30 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
JP2010503663A (ja) * 2006-09-15 2010-02-04 エコ・ファーマシューティカルズ・ビー．ブイ． 医薬活性物質を含む顆粒剤とその製造方法
US10092715B2 (en) * 2006-09-27 2018-10-09 Niconovum Usa, Inc. Directional use
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
US9035130B2 (en) 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
BRPI1013539A2 (pt) * 2009-04-23 2016-04-12 Londonpharma Ltd composição farmacêutica sublingual compreendendo um óleo neutro
ES2409055T3 (es) 2009-06-29 2013-06-24 Bender Analytical Holding B.V. Sistema de suministro de fármacos que comprende polioxazolina y un agente bioactivo
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
CN104363890B (zh) 2012-05-07 2018-01-26 回音制药公司 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元
US9199960B2 (en) * 2013-05-02 2015-12-01 Frederick R. Ferri Method and apparatus for processing herbaceous plant materials including the cannabis plant
US9333229B2 (en) * 2013-10-16 2016-05-10 William Bjorncrantz Winterized crude cannabis extracts and methods of preparation and use
US9616025B2 (en) 2013-10-29 2017-04-11 Echo Pharmaceuticals B.V. Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
WO2015065179A1 (en) 2013-10-29 2015-05-07 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US11033493B2 (en) * 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
IL249197B2 (en) 2014-05-29 2024-09-01 Insys Pharma Inc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
AU2015292915B2 (en) 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
NZ731248A (en) 2014-10-21 2024-04-26 United Cannabis Corp Cannabis extracts and methods of preparing and using same
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016126592A1 (en) 2015-02-02 2016-08-11 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
EP3277260B1 (de) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Pflanzenextrakte aus erodium crassifolium l'her und verwendungen davon
AU2016267585C1 (en) * 2015-05-28 2023-02-16 Fresh Cut Development, Llc Stable cannabinoid formulations
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10751320B2 (en) 2015-07-08 2020-08-25 Flavocure Biotech, Llc Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders
US10456435B2 (en) 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
US10092855B2 (en) 2015-07-16 2018-10-09 Fritz Chess CO2 extraction and filtration system
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
US20180280464A1 (en) * 2015-10-15 2018-10-04 Preleve Therapeutics, Llc Compositions and Methods for Pain Relief
IL244278A0 (en) * 2016-02-24 2016-07-31 Cannabics Pharmaceuticals Inc An ingredient containing cannabinoids, methods for its preparation and its uses
ITUB20161247A1 (it) * 2016-03-02 2017-09-02 Labomar S R L Compressa orodispersibile contenente un principio attivo liposolubile
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
MX2018012685A (es) 2016-04-18 2019-06-06 Michael Morrow Kenneth Aislamiento de extractos de plantas.
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
US11529329B2 (en) 2016-05-27 2022-12-20 Nordiccan A/S Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin
CA3026274A1 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
EP3471746A4 (de) 2016-06-15 2020-02-26 India Globalization Capital, Inc. Verfahren und zusammensetzung zur behandlung von krampfanfällen
US10765658B2 (en) * 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
CN109475586A (zh) 2016-06-29 2019-03-15 康纳塞斯创新公司 脱羧的大麻树脂、其用途和制备其的方法
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
WO2018022669A1 (en) * 2016-07-25 2018-02-01 Ebbu, LLC New cannabis tablet formulations and compositions and methods of making the same
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
US20200215022A1 (en) * 2016-12-20 2020-07-09 Tilray, Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy
AU2018210690B2 (en) * 2017-01-23 2020-12-03 CannTab Therapeutics Limited Immediate release cannabidiol formulations
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CA3055271A1 (en) 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating inflammatory diseases
US10596485B2 (en) 2017-04-03 2020-03-24 Fritz Chess Multi-functional distiller
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
US20200146984A1 (en) * 2017-06-27 2020-05-14 Panaxia Pharmaceutical Industries Ltd. Combination of cannabinoids and at least one additional ingredient for the enhancement of therapeutic potency
WO2019055118A2 (en) * 2017-07-13 2019-03-21 Tab Protein, Llc COMPLEMENTARY FOOD TABLE AND PACKAGING
EP3687527A4 (de) * 2017-09-25 2021-05-26 Canopy Health Innovations Zusammensetzungen mit cannabidiol, tetrahydrocannabinol, terpenen und flavonoiden und ihre verwendung zur behandlung von schlaflosigkeit
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
AU2018345814A1 (en) * 2017-10-05 2020-05-14 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
GB2567240B (en) 2017-10-09 2022-04-06 Senzer Ltd An inhaler particularly a cannabinoid inhaler and a method of assembling such an inhaler
MX2020005697A (es) * 2017-12-01 2020-10-28 Healthy Option Consulting Inc Capsula blanda de gel liquido de doble camara y metodo para administrar composiciones de cannabis sublinguales e ingeribles.
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
AU2019206649B2 (en) 2018-01-12 2024-11-14 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery
WO2019159185A1 (en) 2018-02-19 2019-08-22 To Pharmaceuticals Llc Compositions and methods for the treatment of protein energy wasting
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
SI25373A (sl) * 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
US12011430B2 (en) 2018-05-11 2024-06-18 Rhodes Technologies Compositions and dosage forms for oral delivery
GB201807801D0 (en) 2018-05-14 2018-06-27 Plantine Holdings Ltd Microparticles
CN112672740A (zh) * 2018-06-15 2021-04-16 康宝动物治疗有限公司 大麻素组合物以及使用大麻素组合物的治疗方法
US20200046643A1 (en) 2018-07-18 2020-02-13 Glatt Gmbh Extended release formulations of cannabinoids
CA3114249A1 (en) * 2018-09-26 2020-04-02 Hexo Operations Inc. Cannabinoid-containing concentrate for making a product for human consumption having an improved taste profile and methods of manufacturing same
CA3128712A1 (en) * 2018-11-30 2020-06-04 Canopy Growth Corporation Water-soluble formulations of cannabinoids or cannabis-derived compounds, methods of making and use
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
US11147805B2 (en) 2019-02-07 2021-10-19 Medipure Pharmaceuticals Inc. Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
PL3920891T3 (pl) 2019-04-17 2024-05-20 Nordiccan A/S Szybko rozpadające się tabletki kannabinoidowe
CA3040547C (en) * 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
EP3969054A4 (de) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC Öllösliche arzneimittelhaltige zusammensetzungen und verfahren zur verwendung davon
DE102019211195A1 (de) * 2019-07-26 2021-01-28 Add Advanced Drug Delivery Technologies Ltd. Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats
AU2020330527A1 (en) * 2019-08-12 2022-02-24 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
MX2022002467A (es) 2019-08-30 2022-05-19 Evie Sa Granulos cargados, su proceso de produccion y sus usos.
CN110604195A (zh) * 2019-09-10 2019-12-24 普洱茶王茶业集团股份有限公司 一种普洱茶保健饮品及其制备方法
CA3154616A1 (en) * 2019-09-20 2021-03-25 Mycotechnology, Inc. Methods for reduction of bitterness in cannabinoids using mycelial materials
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
EP3808341A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
WO2021076936A1 (en) * 2019-10-18 2021-04-22 Natural Extraction Systems, LLC Compositions comprising cannabinoid molecules that are dissolved in water-miscible solvents
WO2021116824A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product comprising a cannabinoid
AU2020401471A1 (en) * 2019-12-09 2022-07-07 Nicoventures Trading Limited Oral product comprising a cannabinoid
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
WO2021116826A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product comprising a cannabinoid
WO2021151212A1 (en) * 2020-01-31 2021-08-05 Hexo Operations Inc. System and method for quantifying, formulating and enhancing user experience profile of cannabis
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US20230210796A1 (en) * 2020-06-01 2023-07-06 Technion Research And Development Foundation Limited Compositions and methods for treating headaches
GB2595692B (en) 2020-06-03 2024-10-23 Senzer Ltd A refill for an inhaler particularly a cannabinoid inhaler
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CA3195100A1 (en) 2020-10-23 2022-04-28 Koji Masuda Cannabidiol-containing seamless soft capsule
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2022200636A1 (en) 2021-03-26 2022-09-29 Insucaps Limited Pharmaceutical formulations, and methods for the production thereof
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023275864A1 (en) * 2021-06-27 2023-01-05 Roxx Labs Ltd. A process for the preparation of aqueous cannabinoid compositions
EP4134073A1 (de) 2021-08-11 2023-02-15 HM HerbaMedica GmbH Pharmazeutische zusammensetzungen mit dendritischen nanoträgern und cannabiswirkstoffen
MX2024009157A (es) 2022-01-28 2024-08-06 Vertanical GmbH Metodo para la produccion de un extracto vegetal.
US20240024253A1 (en) * 2022-07-21 2024-01-25 Pike Therapeutics Inc. Continuous Drug Delivery Systems and Methods
WO2024189150A1 (en) * 2023-03-14 2024-09-19 Dsm Ip Assets B.V. Cannabinoid formulations

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3504384A (en) 1963-10-23 1970-04-07 Russell Research Ltd Toilet bowl cleaning and disinfecting device
US3560625A (en) 1967-02-20 1971-02-02 Colgate Palmolive Co Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system
GB1466560A (en) 1974-02-05 1977-03-09 Jeyes Group Ltd Bleach compositions
US4248827A (en) 1978-06-12 1981-02-03 The Procter & Gamble Company Method for sanitizing toilets
US4200606A (en) 1978-12-22 1980-04-29 The Procter & Gamble Company Method for sanitizing toilets
GB8325541D0 (en) 1983-09-23 1983-10-26 Unilever Plc Liquid thickened bleaching composition
DE3419169A1 (de) 1984-05-23 1985-11-28 Henkel KGaA, 4000 Düsseldorf Dosiervorrichtung
GB8603300D0 (en) 1986-02-11 1986-03-19 Unilever Plc Bleaching composition
US5034150A (en) 1989-05-03 1991-07-23 The Clorox Company Thickened hypochlorite bleach solution and method of use
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
NL9101759A (nl) 1991-10-22 1993-05-17 Sara Lee De Nv Vloeibaar-reinigings- en/of verfrissingsmiddel voor een toiletpot.
GB2285921A (en) * 1994-01-31 1995-08-02 Leilani Lea Sublingual administration of medicaments
EP0788346B9 (de) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
ES2124204T1 (es) 1995-11-22 1999-02-01 Sara Lee De Nv Sistema limpiador/ambientador de inodoro.
NL1001722C2 (nl) 1995-11-22 1997-05-23 Sara Lee De Nv Reinigings- en verfrissingseenheid bestemd om te worden opgehangen aan een toiletpotrand.
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6113940A (en) * 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
DE69936640D1 (de) * 1998-04-21 2007-09-06 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
GB2361250B (en) 1998-06-15 2002-10-23 Johnson & Son Inc S C Unit for dispensing a liquid from the rim of a lavatory bowl
GB2345494A (en) 1998-06-15 2000-07-12 Johnson & Son Inc S C Unit for dispensing a liquid into a toilet bowl
US20020039795A1 (en) * 1998-10-26 2002-04-04 Elsohly Et Al Method of preparing delta-9-tetrahydrocannabinol
DE19912217C2 (de) 1999-01-12 2002-09-05 Jeyes Deutschland Gmbh Vorrichtung zur Abgabe von Wirkstoffen in das Spülwasser insbesondere in Toilettenbecken
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001003668A1 (en) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Pulmonary delivery of liposome-encapsulated cannabinoids
ATE397698T1 (de) 1999-11-02 2008-06-15 Jeyes Group Ltd Flüssigkeitsabgabevorrichtungen
CN1258359C (zh) * 2000-03-09 2006-06-07 Gw药品有限公司 药物组合物
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2368576A (en) 2000-11-02 2002-05-08 Brian Parry Slade Liquid delivery device having a layer of textile material
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
AU2002319422C1 (en) * 2001-07-10 2008-05-01 Norton Healthcare Limited Aerosol formulations of delta8 tetrahydrocannabinol

Also Published As

Publication number Publication date
ZA200306074B (en) 2005-01-26
EP2286793A3 (de) 2014-01-08
CA2438097A1 (en) 2002-08-22
EP1361864B1 (de) 2013-12-04
EP2292211A2 (de) 2011-03-09
HUP0303182A2 (hu) 2003-12-29
EP2298284A3 (de) 2013-12-18
EP2298283A3 (de) 2012-12-26
NZ527289A (en) 2005-05-27
PT1361864E (pt) 2014-03-03
KR100886668B1 (ko) 2009-03-04
NO20033556L (no) 2003-10-09
JP2005512943A (ja) 2005-05-12
HU227452B1 (en) 2011-06-28
NO20033556D0 (no) 2003-08-11
EP2286793A2 (de) 2011-02-23
AU2002231970B2 (en) 2007-08-16
DK1361864T3 (en) 2014-03-03
EP1361864B9 (de) 2014-07-09
MXPA03007215A (es) 2003-12-04
ES2444641T3 (es) 2014-02-26
EP2298283A2 (de) 2011-03-23
WO2002064109A2 (en) 2002-08-22
IL157130A0 (en) 2004-02-08
DE10296335T5 (de) 2004-04-15
CZ20032458A3 (cs) 2003-11-12
NO334743B1 (no) 2014-05-19
EP1361864A2 (de) 2003-11-19
GB2388543A (en) 2003-11-19
SI1361864T1 (sl) 2014-04-30
KR20030074835A (ko) 2003-09-19
EP2298284A2 (de) 2011-03-23
JP4467883B2 (ja) 2010-05-26
CA2438097C (en) 2006-04-25
CZ306277B6 (cs) 2016-11-09
EP2292211A3 (de) 2014-01-01
WO2002064109A3 (en) 2003-02-20
GB0319041D0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
HK1056509A1 (en) Liquid spray formulations for buccal delivery of cannabinoids
IL161214A0 (en) Compositions for delivery of drug combinations
EP1416884A4 (de) Abgabe von mitteln mit therapeutischen eigenschaften
IL162294A0 (en) Formulation & dosage form for the controlled delivery of therapeutic agents
IL161446A0 (en) Medicinal compositions for nasal absorption
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
HUP0401116A3 (en) Stable liquid peticide compositions
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
EG24078A (en) Liquid pharmaceutical composition
IL159722A0 (en) Pharmaceutical compositions containing oligonucleotides
GB0122725D0 (en) Drug dispensing components
EP1663783A4 (de) Flüssigkeitszufuhrsystem für gasmaske
IL160375A0 (en) Pharmaceutical compositions comprising lumiracoxib
IL158255A0 (en) Compositions containing imidazotriazinone for nasal application
HK1064953A1 (en) Compositions for nasal administration of insulin
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2002240942A1 (en) Improved delivery of benefit agents
GB2378186B (en) Mild antimicrobial liquid cleansing formulations
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
GB2385115B (en) Liquid Dispensing Nozzle
HUP0103049A3 (en) Use of fluexetine for preparation of pharmaceutical compositions
GB0114844D0 (en) Formulation delivery
GB0124010D0 (en) Pharmaceutical compositions for inhalation

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220213